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Abstract (Cerebral cortex max 200 words) 
Sleep problems relate to brain changes in aging and disease, but the mechanisms are unknown. 
Studies suggest a relationship between β-amyloid (Aβ) accumulation and sleep, which is likely 
augmented by interactions with multiple variables. Here, we tested how different cerebrospinal 
fluid (CSF) biomarkers for brain pathophysiology, brain atrophy, memory function, and 
depressive symptoms predicted self-reported sleep patterns in 91 cognitively healthy older 
adults over a 3-year period. The results showed that CSF levels of total- and phosphorylated (P) 
tau, and YKL-40-a marker of neuroinflammation/astroglial activation-predicted poor sleep in Aβ 
positive older adults. Interestingly, although brain atrophy was strongly predictive of poor 
sleep, the relationships between CSF biomarkers and sleep were completely independent of 
atrophy. A joint analysis showed that unique variance in sleep was explained by P-tau and the 
P-tau × Aβ interaction, memory function, depressive symptoms, and brain atrophy. The results 
demonstrate that sleep relates to a range of different pathophysiological processes, 
underscoring the importance of understanding its impact on neurocognitive changes in aging 
and people with increased risk of Alzheimer's disease. 
 




Sleep problems may be both causative and indicative of brain health in normal aging 1 and age-
related degenerative conditions 2-4. Hence, understanding the causes of sleep problems is 
critical. Especially interesting is the putative relationship between sleep and the Alzheimer’s 
disease (AD) biomarker Aβ. Sleep disturbances may drive pathogenesis early in the course of 
neurodegeneration 5, but evidence also indicates that Aβ accumulation can cause sleep 
problems 6, which again may reduce the brains ability to clear Aβ in a positive feedback loop. 
Several studies have reported that sleep problems are associated with accumulation of Aβ even 
in healthy older adults 6-12, but the relationships are usually relatively week, with different sleep 
parameters affected across studies. Combined with the multi-factorial nature of age-related 
degenerative diseases 13, 14, this implies that it is necessary to explore mechanisms working in 
synergy with Aβ to cause sleep problems. We approached this challenge by testing whether 
different CSF biomarkers of relevance for sleep problems interacted with Aβ in predicting sleep 
quality over a 2 year period in cognitively healthy older adults. 
 
First, tau may be of special relevance to sleep15 because neurofibrillary tangles originate in the 
medial temporal lobe (MTL)16, and hippocampus is critical for non-rapid eye movement (NREM) 
sleep spindles and slow waves supporting sleep-dependent memory processing 17, 18. 
Accordingly, some studies found CSF levels of tau to be associated with sleep problems 19-21. 
Thus, understanding possible synergistic relationships between Aβ and tau pathology in 
accounting for sleep problems is a major task: Is the impact of Aβ and tau on sleep inter-related 
or independent, and do these interactions forecast the progression of cognitive decline 15? 
Second, the inflammation and astroglial activation marker YKL-40 (chitinase-3-like protein-1) 
has been extensively researched in relation to sleep conditions such as obstructive sleep apnea 
22-26, but it has not been tested whether neuroinflammation also impact age-related sleep 
problems. This is an interesting hypothesis because CSF levels of YKL-4027 increase with age 28 
and AD 27, 29-31 (but see 32). Inflammation is also related to brain atrophy 33, 34 and is assumed to 
start early in the cascade of neurodegeneration, as damaged neurons, insoluble Aβ deposits 
and neurofibrillary tangles provide prime stimuli for inflammation 35, 36. Thus, it is possible that 
YKL-40 could interact with Aβ in predicting sleep problems. Third, neurofilament light (NFL), 
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reflecting axonal degeneration 37, 38, has recently been shown to predict hippocampal atrophy 
in mild cognitive impairment 39 and normal aging 40. As argued above, biomarkers related to 
MTL atrophy are potentially useful tools to help us understand mechanisms for sleep 
disturbances in aging and neurodegeneration.  
 
In the present study we tested whether CSF levels of tau, YKL-40 and NFL interacted with Aβ in 
prediction of sleep quality over a 2 year period. Since even normal aging is associated with 
brain atrophy41-43 and sleep problems are related to increased atrophy in older adults 44, we 
further tested whether CSF biomarkers predicted sleep problems independently of brain 
atrophy, or indirectly by impacting atrophy rates. Finally, as sleep has consistently been related 
to levels of depression and memory function 15, 45, these variables were also included in the 
final model. 
 
Materials and Methods 
Sample 
The study was conducted in accordance with the Declaration of Helsinki and approved by the 
Regional Committee for Ethics in Medical Research in Norway (REK 2011/2052). All participants 
provided written informed consent. General recruitment and screening procedures are 
previously described in Idland et al. 40. In short, patients were scheduled for elective 
gynecological (genital prolapse), urological (benign prostate hyperplasia, prostate cancer or 
bladder tumor/cancer) or orthopedic (knee or hip replacement) surgery in spinal anesthesia 
turning 65 years or older the year of inclusion. Dementia, previous stroke with sequela, 
Parkinson’s disease and other neurodegenerative diseases likely to affect cognitive function 
were initial exclusion criteria. From this pool of participants, we further selected only 
cognitively healthy participants based on clinical examinations at Department of Geriatric 
Medicine, and participants offered referral to cognitive assessment were excluded. The full 
sample with available relevant data then consisted of 91 participants. Three participants had 
MMSE score < 27 at baseline. None of these dropped more than one point during the two year 
follow up interval, and the one with a score below 25 at baseline (23) improved to 30 at the 
5 
 
follow up.  Thus, these three patients were included in the analyses. 4 participants with CSF NFL 
levels > 4000 pg/mL (i.e. more than ± 3 SD from the mean value) were excluded. After these 
criteria, the sample with baseline CSF and PSQI data counted 91 (mean age 72 years, range 64-
89), while longitudinal MRI data were available for 78 of these. Sample characteristics are 
described in Table 1. 
 
[Insert Table 1 about here] 
 
Participants were assessed with a multi-domain battery of cognitive tests before surgery, 
comprising the Mini Mental Status Examination (MMSE) 46, Clock Drawing Test 47, Word List 
Memory Task 48, Trail Making Test A and B 49, Kendrick Object Learning Test 50, and verbal 
fluency (FAS test and Animal Naming) 51. Blood and CSF samples were collected by the 
anesthesiologist in conjunction with spinal anesthesia, and participants underwent magnetic 
resonance imaging (MRI) after surgery. The mean time between CSF sampling and MRI at 
baseline was 8 weeks. Participants underwent a second MRI and were tested with the same 
battery of cognitive tests at two-year follow-up (mean time between MRIs = 2.2 years, SD = 
3.3).  
 
Magnetic resonance imaging acquisition and processing 
T1-weighted MPRAGE 3D images were acquired with a 1.5 T Siemens Avanto scanner using a 
12-channel head coil (TR=2400 ms, TE=3.79ms, Field of View=240mm, slice thickness=1.20mm, 
pixel size=1.25x1.25mm). Images were processed with the longitudinal stream in FreeSurfer 5.3 
(https://surfer.nmr.mgh.harvard.edu). For each MRI, the FreeSurfer pipeline performs a set of 
automated procedures for the cortical reconstruction and volumetric segmentation, 
documented elsewhere 46, 47. The FreeSurfer longitudinal stream includes methods designed to 
minimize the bias to any time point which lead to increased statistical power, better separation 
of groups based on atrophy, and higher reproducibility. These include the generation of a 
subject-specific intermediate template followed by a projection of each time point to this 
template 48, 49. For both the individual and longitudinal processing steps, reconstructed surfaces 
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and volumes were visually inspected and manually corrected when necessary. The output 
included in the present analyses was symmetrized percent change in volume, thickness and 
area for each of 33 cortical regions in each hemisphere 50. 
 
APOE genotyping 
Blood samples were genotyped for APOE (gene map locus 19q13.2) using TaqMan Allelic 
Discrimination technology (Applied Biosystems, Carlsbad, CA, USA). Genotypes were obtained 
for the two SNPs that are used to unambiguously define the ε2, ε3, and ε4 alleles (rs7412 and 
rs429358).  
 
CSF collection and analyses 
CSF was collected in polypropylene tubes, centrifuged at room temperature for 10 minutes, the 
supernatant aliquoted into polypropylene tubes, and frozen at -80 °C pending analyses. Mean 
time from CSF sampling to freezing was 83 minutes (SD, [range]: 21, [30 to 127]).  Samples were 
sent on dry ice to the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital, 
Mölndal, Sweden, for analyses. CSF Aβ42, total tau (T-tau) and P-tau concentrations were 
determined using INNOTEST enzyme-linked immunosorbent assays (Fujirebio, Ghent, Belgium), 
CSF NFL concentrations using a commercial ELISA (UmanDiagnostics, Umeå, Sweden) and YKL-
40 concentrations were measured using a commercially available ELISA (R&D systems, 
Minneapolis, MN). Analyses were performed by board-certified laboratory technicians masked 
to clinical data. Intra-assay coefficients of variation were 9-13%. We defined Aβ positive as 
values below 550 pg/mL, which is within conventionally used cut-off values for CSF Aβ42 
described in the literature, ranging from 500 to 650 pg/mL 51-54. 
 
Sleep assessment 
Sleep quality was assessed after the second MRI using the Pittsburgh Sleep Quality Inventory 
(PSQI)55 in Norwegian. PSQI is a well-validated self-rated questionnaire that assesses seven 
domains of sleep quality (sleep quality, latency, duration, efficiency, problems, medication and 
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daytime tiredness) in addition to a global score over a 1-month time interval. The minimum 
score is 0 and maximum score is 3 for each domain, while the global score ranges from 0 to 21. 
 
Statistics 
First, Pearson correlations were run to test the relationship between sleep and a number of 
confounding variables to decide which should be included as covariates in the following 
analyses: age, body mass index (BMI), cholesterol, vitamin D and docosahexaenoic acid (DHA: 
C226n3). To test the relationship between CSF biomarkers and sleep, multiple regressions were 
run with total sleep score as dependent variable and each of the biomarkers T-tau, P-tau, YKL-
40 and NFL in turn as predictors, on the form 
Sleep = C + β1×Age + β2×Biomarker + β3×Aβ status + β4×(Aβ status×Biomarker). This way we 
could test whether each biomarker was differentially related to sleep as a function of Aβ status. 
As APOE has been shown to impact the relationship between sleep and neurofibrillary tangle 
pathology 56, additional models were run with APOE as covariate. Post hoc analyses were run 
with the different PSQI sub-scores as dependent variables. All variables were z-transformed to 
avoid problems with multicollinearity. 
 
To test whether effects of biomarkers on sleep could be explained by brain atrophy, we first ran 
a stepwise multiple regression analysis to identify the optimal linear combination of brain 
variables to account for the variation in PSQI Global. In the first step, age was forced into the 
model. In the second step, symmetrized percent change (SPC) in thickness, area and volume in 
all 33 cortical regions were entered and removed in an iterative stepwise manner. The regions 
included in the final model were then added as additional covariates in the multiple regression 
models with the CSF biomarkers, and the β’s were inspected. Substantial reduction in the β’s 
for the CSF biomarkers in the prediction of sleep problems would be taken as evidence that 
brain change could account for the sleep – CSF biomarker associations. 
 
To test the relationship between sleep and clinical and cognitive outcome variables, partial 
correlations between PSQI Global and the Montgomery and Åsberg Depression Rating Scale 
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(MADRS)57 at baseline as well as at follow up, controlling for the effects of age and sex. Further, 
PSQI Global was correlated with the total score and the number of items recalled from the 
verbal memory test from the CERAD battery at follow up (The Consortium to Establish a 
Registry for Alzheimer’s Disease)58, as well as the symmetrized change between baseline and 
follow up, again controlling for age and sex. Analyses were also run of MADRS and CERAD 
verbal memory simultaneously to test for the specificity of the relationships. 
 
Finally, path analysis implemented in SPSS AMOS was conducted in an attempt to integrate all 
tested variables in one comprehensive model. Based on the results from the multiple 
regression analyses and the partial correlations, we constructed an initial model which included 
paths between most variables. This model was then recursively improved by removing paths 
not significant one by one and re-running the model multiple times, until all paths were 
significant. Akaike Information Criterion (AIC) 59 was used to guide model selection. 
 
Results 
Identification of confounding variables 
Pearson correlations between PSQI and a number of potential confounding variables are shown 
in Supplemental Table 1. None of the variables correlated significantly (all p’s > .3) with PSQI 
Global. Higher age was significantly associated with Component 4 - less sleep efficiency (r = .28, 
p < .01) and Component 7 – tired (r = .21, p < .05). Thus, age was included as covariate in all 
analyses. The other tested variables were not included in further analyses. 
 
Relationship between CSF biomarkers and sleep 
Total tau and p-tau 
First, the models were run with tau, age, Aβ status and tau × Aβ interaction as covariates. An 
interaction with Aβ was found for T-tau (β = .63, p = .046) and P-tau (β = .68, p = .032) with PSQI 
Global. Post hoc analyses revealed a significantly stronger positive correlation between tau and 
PSQI Global in the Aβ+ group (total-tau: r = .42; p-tau r = .45) compared to the Aβ- group (total-
tau: r = .00; p-tau: r = -.01). The Aβ interactions survived inclusion of APOE status and tau × 
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APOE status interactions for P-tau (β = .74, p = .043), while for T-tau, the slight increase in p-
value rendered the interaction significant at a trend level only (β = .72, p = .066). No other 
terms were significant in these models. Post hoc tests were then run to test for relationships 
with specific PSQI sub components. The tau-Aβ interaction was significant for Component 1 
Sleep quality for both P-tau (β = .67, p = .035) and T-tau (β = .64, p = .045), and for Component 
6 Medication (P-tau: β = .69, p = .026; T-tau: β = .70, p = .025). For Component 6, there were 
also main effects of Aβ (model with P-tau: β = .21, p = .043; model with T-tau β = .21, p = .047). 
 
When all covariates except age were removed, significant relationships between tau and 
Component 2 sleep latency was found (T-tau: β = .23, p = .034; P-tau: β = .22, p = .047), not 
interacting with age.  
 
YKL-40 
YKL-40 interacted with Aβ in prediction of PSQI Global (β = .73, p = .026). This was due to a 
stronger relationship in Aβ+ (r = .33) than Aβ- participants (r = -.07). Post hoc analyses revealed 
significant YKL-40 × Aβ interactions for Component 1 Sleep quality (β = .79, p = .016), 
Component 6 Medication (β = .95, p = .003) and Component 7 Tired (β = .72, p = .025). Adding 
APOE as well as the YKL-40 × APOE interaction increased the YKL-40 × Aβ p-value somewhat for 
PSQI Global, yielding significance at a trend level only (p = .081). YKL-40 was not related to PSQI 
Global if Aβ status was not taken into account. 
 
NFL 
NFL was not significantly related to PSQI Global in the full model including Age and Aβ, and did 
not interact with Aβ (β = -.13, n.s.). Removing Aβ from the model revealed no significant effects 
on PSQI Global.  
 
Effects of atrophy 
A stepwise multiple regression analysis was first run to identify the optimal linear combination 
of brain variables to account for PSQI. In the first step, Age was forced into the model. In the 
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second step, symmetrized percent change in thickness, area and volume in all 33 cortical 
regions were entered and removed in an iterative stepwise manner. The final model consisted 
of 7 brain variables (see Table 2), all significantly related to PSQI. Adjusted R2 was .30 (p 
< .00005) and all variables except age were significant (p < .05). Removing age from the model 
slightly increased adjusted R2 to .31. A post hoc analysis showed that there was no interaction 
between atrophy and Aβ-status in prediction of PSQI (β = -.02, n.s.).  
 
[Insert Table 2 about here] 
 
After having established the optimal linear combination of brain variables, these were entered 
into a multiple regression analysis together with age, tau, Aβ-status and the Aβ × tau 
interaction to test whether the brain variables could account for the relationship between sleep 
and the CSF biomarkers. The Aβ × tau interaction survived the inclusion of all the brain 
variables, with an even higher beta (β = .75, p < .05). The adjusted R2 for this model was .37 (p 
< .00001). The results for p-tau were similar, with the interaction with Aβ still significant (β 
= .83, p < .01) and a good overall model fit (adjusted R2 .39, p < 00001). 
 
The same analyses were then run for YKL-40. As for tau, the interaction with Aβ survived 
introduction of all the brain change variables (β = .65, p < .05), and the total model was 
significant with an adjusted R of .36 (p < 00005). 
 
Post hoc, these analyses were repeated with sex, BMI and interval between MRIs in turn as 
additional covariates. Adding sex or interval did not affect any of the reported relationships. 
Adding BMI, the Aβ × P-tau interaction was still significant, while the p-values for the Aβ × T-tau 
and Aβ × YKL-40 interactions increased slightly (t-tau: β = .64, p =.061; YKL-40: β = .58, p =.069). 
The contributions from BMI were not significant in any of the models, the changes in β’s for the 
interaction terms were not significant, and the model fits did not improve (T-tau: adjusted R2 
reduced from .37 to .36, for YKL-40 from .36 to .35). Thus, including BMI in the final models was 
11 
 
not justified, but we still report that BMI may exert a minor influence on the Aβ-interaction 
terms. 
 
Relationship to clinical and cognitive outcomes 
We ran partial correlations between PSQI Global and MADRS at baseline and follow up, 
controlling for the effects of age and sex. Significant partial correlations were found at both 
time-points (Baseline: r = .56, follow up r = .46, p < .00001). Further, we correlated PSQI Global 
with the total score and the number of items recalled from the verbal memory test from CERAD 
at follow up, again controlling for age and sex, and found significant correlations both for the 
total score (r = -.22, p < .05) and for the number of items remembered (r = -.27, p < .05). No 
significant correlations between PSQI and change in memory score between baseline and 
follow up were seen, only a trend for number of items recalled (r = -.18, p = .099), indicating 
that worse longitudinal memory outcome tended to be associated with higher PSQI score. The 
results for the PSQI subcomponents are reported in Table 3. 
 
[Insert Table 3 about here] 
 
We re-ran the memory-PSQI correlations controlling for MADRS scores, and the MADRS-PSQI 
correlations controlling for memory scores, in both cases also controlling for age and sex. The 
memory-PSQI correlations were not significant, with a trend only for number of items 
remembered (r = -.20, p = .07). The MADRS-PSQI correlations were still significant (r = .53 
and .47 for baseline and follow-up, respectively, both p’s < .00001). 
 
Path analysis 
Path analysis was conducted to integrate all tested variables in one comprehensive model. PSQI 
Global score was used as outcome. As a single measure of atrophy, we used the standardized 
predicted values from the stepwise regression analysis described above (Table 2). P-tau was 
preferred over t-tau, and the CERAD 10 words number of item recalled was used as the 
measure of memory. Further we included age, MADRS score at follow up and YKL-40, as well as 
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the Aβ × P-tau and Aβ × YKL-40 interaction terms. The initial model, with paths between most 
variables, is shown in Supplemental figure 1. This model was recursively improved by removing 
not significant paths one by one (p < .1 as criterion for removal) and re-running the analysis 
multiple times. This procedure led to a model with significant paths from age to MADRS, YKL-40 
and the Aβ × YKL-40 interaction term, from atrophy to MADRS score and PSQI, from the Aβ × P-
tau interaction and P-tau to PSQI, from MADRS to PSQI, from PSQI to CERAD (p = .055), and 
from YKL-40 and the Aβ × YKL-40 interaction term to CERAD. The paths from Aβ status to PSQI 
and CERAD were not significant, but were initially kept in the model to ease interpretation of 
the Aβ × P-tau and Aβ × YKL-40 interactions. AIC for this model was 307. Removing Aβ status 
from the model rendered all paths significant at p < .05, except from PSQI to Memory, p = .066, 
and AIC decreased to 291. Swopping the direction of the path from PSQI  Memory to 
Memory  PSQI, caused this path now to be significant, and resulted in all 11 paths being 
significant. This further lowered AIC to 290, indicating that this may be the preferred model. 
The model is shown in Figure 1. Detailed model statistics for these two models are presented in 
Supplementary Table 2. In this model, 50% of the variance in sleep was explained (adjusted R2 
= .50, unadjusted R2 = .58) (see Figure 2).  
  
[Insert Figure 1 and Figure 2 about here] 
 
Discussion 
The results showed that CSF levels of tau and YKL-40 interacted with amyloid status in 
predicting sleep characteristics over two years in cognitively healthy older adults. Further, sleep 
was predicted from multiple variables, with memory function, depression, brain atrophy, p-tau 
and Aβ × p-tau interaction all yielding unique contributions. This suggests that sleep is a 
complex variable affected by a range of different processes in the brain. Thus, age-related 
changes in sleep patterns can have multiple causes, which will likely be partly independent, 
partly overlapping and partly synergistically in explaining sleep disturbances.   
 
Aβ interact with tau and YKL-40 in predicting sleep 
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The relationship between Aβ accumulation and sleep problems has received much attention. 
Animal studies suggest that Aβ clearance is most efficient during sleep, and that disturbed sleep 
will lead to increased Aβ accumulation in the brain 60. Further, several studies have reported 
that sleep problems are associated with accumulation of Aβ-proteins even in healthy older 
adults 6, 7. For instance, at least four recent studies using amyloid Positron Emission 
Tomography (PET) have found relationships between self-reported sleep parameters and Aβ-
accumulation 8-11. Importantly, however, the relationships reported are usually relatively weak, 
and the exact sleep parameter showing relationship to Aβ varies. Of the studies cited above, 
significant relationships with Aβ were found for 1 of 6 sleep variables tested 9, 1 of 4 8, 3 of 7 10 
and 1-2 (depending on which covariates were used) of 5 11. This suggests that the direct 
association between self-reported sleep problems and Aβ is not strong. This conclusion 
warrants efforts to look at other pathways to sleep problems, which may work in synergy with 
Aβ. 
 
There have been few attempts to test how different biomarkers may interact with Aβ in causing 
sleep disturbances. We found tau to predict poorer sleep better in Aβ positive compared to Aβ 
negative older adults. This is interesting, as tau accumulation in MTL is one of the first events in 
AD, likely prior to Aβ accumulation16, and MTL is critical for many aspects of sleep15, 17, 18. In 
rodents, MTL tau diminishes expression of hippocampal ripples, causing less temporally 
synchronized ripple events 61 and disrupted network activity during sleep 62. Human studies 
have also reported relationships between tau and sleep patterns19-21. In one study, better sleep 
was associated with less neurofibrillary tangle density at autopsy, attenuating the effect of 
APOE ɛ4 56. In this study, no direct effect of sleep was found on plaque load, and sleep modified 
the APOE effect on tangle density in a manner not statistically mediated by Aβ. In the model 
used in the present study, sleep was predicted from tau, since tau was observed at an earlier 
point in time. However, in reality, the causality may go both ways. For instance, long-term sleep 
deprivation has been shown to lead to memory decline and disruptions of tau processing in 




The findings indicate that both Aβ and tau accumulation is related to sleep, in possible vicious 
causative cycles, leading to the crucial question of if and how they are redundant, independent 
or work synergistically in explaining sleep. The present results showed that tau is more 
predictive of sleep patterns over 2 years in Aβ positive than Aβ negative older healthy adults. 
This can be interpreted within a neural reserve model, where certain levels of Aβ or tau can be 
coped with without causing sleep problems, but not when faced with high levels of both.  
 
In addition to tau, the neuroinflammation/astroglial activation marker YKL-40 also interacted 
with Aβ in predicting sleep. YKL-40 in serum has been related to specific sleep conditions and 
disturbances22-26. Aβ accumulation provides prime stimuli for inflammation Aβ35, 36, which could 
contribute to explain the interaction between Aβ and YKL-40. CSF levels of YKL-4027 increase 
with age 28 and in AD 27, 29-31 (but see 32), and is related to brain atrophy 33, 34. Put together, 
these factors can explain why YKL-40 may play a crucial role in age-related sleep disturbances. It 
must be noted, however, that when all variables were included in the path model, YKL-40 no 
longer predicted sleep directly, only indirectly through its relationship with memory function.  
 
We and others have recently shown that NFL is related to hippocampal atrophy39, 40, but NFL 
did not interact with Aβ in predicting sleep problems in the current dataset. Further studies are 
necessary to establish whether NFL is related to sleep characteristics.  
 
Multiple variables predicted sleep 
Importantly, the path analysis demonstrated that multiple variables uniquely predicted sleep 
patterns. In addition to the tau × Aβ interaction, brain atrophy, memory function and 
depression scores were related to the global sleep variable. This demonstrates the complex 
nature of sleep, and that variation in sleep patterns index a range of different processes. In the 
preferred model, sleep was a purely exogenous variable, with a better fit for example when 
causality was modelled from memory to sleep rather than the other way around. Of course, this 
should not be taken as evidence that the mechanisms work only one way, as there for instance 
are obvious effects of sleep on memory function 45, 65, 66 and experimental rodent studies 
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suggesting possible pathways from sleep deprivation to tau 63, 64 and Aβ accumulation 5. Still, 
the results underscores that sleep may be an important variable related to brain health and 
cognitive function in older adults at increased risk of Alzheimer’s disease. 
 
Limitations 
There are several limitations to the present study. First, although sleep was measured by a well-
validated and much used inventory, it is still a self-report measure. The strength of this 
approach is that sleep is measured in the participants’ natural environment, increasing its 
ecological validity. Complementary evidence from actigraphy would strengthen the 
conclusions. Second, participants with cognitive decline were screened out. This may have 
biased the sample, as for instance older adults with high rates of atrophy, Aβ accumulation and 
sleep problems also would be more likely to be excluded, thus possibly reducing the observed 
interrelations between the variables of interest. Still, this approach allowed us to study the 
relationships among multiple variables in the very important group of cognitively well-
functioning older adults with different Alzheimer risk profiles, among other things representing 
the most promising time window for possible intervention. Finally, although CSF measures yield 
highly accurate indexes of total biomarker levels, we do not get information about where in the 
brain accumulation is largest, which is a benefit of e.g. amyloid PET. 
 
Conclusion 
The present results demonstrate that Aβ interact with tau and YKL-40 in predicting sleep 
problems. Further, tau, the tau × Aβ interaction, memory function, depression score and brain 
atrophy explained unique variance in sleeping patterns, clearly suggesting that sleep is a 
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Figure 1 Path model 
This model was obtained after removing all not significant paths. As can be seen, the global 
sleep index is uniquely predicted from five variables. Numbers represent partial standardized 
paths coefficients, and all shown coefficients were significant (p < .05). 
 
Figure 2  
Scatterplot showing the prediction model (x-axis) and total sleep problems (PSQI total score). 
The prediction model consisted of age, P-tau, Aβ-status, the Aβ × tau interaction and two year 
change in seven different cortical regions (see Table 2). In total, this model accounted for 58% 
of the variance in sleep problems. Similar results were obtained for T-tau and YKL-40. 
 
 
 
 
